Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Quadria Cap Invests Rs...

    Quadria Cap Invests Rs 475.31 crore investment in Concord Biotech

    Written by savita thakur thakur Published On 2016-07-06T11:40:59+05:30  |  Updated On 6 July 2016 11:40 AM IST
    Quadria Cap Invests Rs 475.31 crore investment in Concord Biotech

    New Delhi : Private equity firm Quadria Capital has concluded a Rs 475.31 crore investment in bio-pharmaceutical active ingredient manufacturer Concord Biotech. The transaction has been carried out through Quadria Capital's Singapore-based SPV, Helix Investments Pte Ltd. Other investors in the SPV are Rising Tide and Neuberger Berman.


    Concord is among the leading manufacturers of fermentation-based biopharmaceutical APIs, focused on niche segments such as immuno suppressant, oncology, anti-fungal and anti-bacterial.


    "We believe that now is the time to take the business to the next level by extending therapy expertise and introducing new range of products. In this pursuit of ours, we are delighted to have a partner like Quadria, who we believe will help us in the next phase of our growth through their domain expertise and global network," Concord promoter Sudhir Vaid said.


    Concord's strong dominance in the fermentation-based biopharma products, and their operating philosophy of delivering complex product categories, firmly positions them to achieve future growth, Quadria Capital Managing Partner Amit Varma said.


    "We are confident of the company's ability to deliver the next phase of growth and will support them along the way through our network and eco-system," he added.


    In May this year, FIPB had cleared a Rs 475.31 crore proposal of Singapore-based Helix Investment Holding to invest 20 per cent in the equity of Concord Biotech by subscribing to equity shares and purchasing them from existing shareholders.


    Concord is coming up with a new formulation facility in Ahmedabad and expects to start operations by the end of 2016. It has been designed to cater to solid and liquid orals both for regulated and semi-regulated markets.

    Amit Varmaanti-bacterialanti-fungalbiopharmaConcord BiotechFIPBHelix InvestmentsInvestmentNeuberger BermanoncologyQuadria CapitalSudhir Vaid
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok